Chemomab Therapeutics Ltd.
CMMBNasdaq
$1.56
↑ +2.6%Jul 17 close · end-of-day
Price
1Y↓ -65.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$796.0M
Enterprise Value
$790.5M
P/E
86.7
P/S
—
P/B
82.1
EV/EBITDA
—
PEG
—
FCF Yield
-1.4%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$9.0M
Free Cash Flow (TTM)
-$11.1M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-92.7%
ROIC
-2081.4%
Debt / Equity
—
Net Cash
$5.4M
Return 1Y
-65.5%
Company profile
Chemomab Therapeutics Ltd. discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24.
- CEO
- Dale R. Pfost
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Website
- chemomab.com
Earnings
CMMB Q2 2025 Earnings
Period ends 2025-06-30
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | — | -$103.0M | -$112.0M |
| Net income | -$6.0M | -$12.5M | -$27.6M | -$24.2M | -$13.9M | -$9.0M |
| Diluted EPS | — | $0.06 | $0.12 | $0.10 | $0.04 | $0.02 |
| Operating cash flow | -$5.2M | -$12.4M | -$20.4M | -$23.6M | -$15.4M | -$11.1M |
| Free cash flow | -$5.3M | -$12.6M | -$20.4M | -$23.6M | -$15.4M | -$11.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q3 '22 | Q4 '22 | Q2 '23 | Q2 '23 | Q2 '24 | Q2 '24 | Q2 '25 | Q2 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$8.1M | -$8.3M | -$8.8M | -$8.0M | -$3.9M | -$3.6M | -$3.3M | -$2.1M |
| Diluted EPS | $0.04 | $0.04 | $0.04 | $0.04 | — | $0.01 | — | — |
| Operating cash flow | -$5.3M | -$5.7M | -$7.2M | -$7.5M | — | — | — | — |
| Free cash flow | -$5.3M | -$5.7M | -$7.2M | -$7.5M | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-29 | Mor George Adi· Chief Executive Officer | Buy | 4,926 | $2.08 | $10,246.08 | filing |
| 2026-05-29 | Mor George Adi· Chief Executive Officer | Buy | 4,878 | $2.05 | $9,999.90 | filing |
| 2026-05-29 | Mor George Adi· Chief Executive Officer | J | 31,712 | — | — | filing |
| 2026-05-29 | Mor George Adi· Chief Executive Officer | J | 18,750 | — | — | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.